Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore

The reports of inflation’s demise, at least if you’ve been listening to the White House, appear greatly exaggerated. 

The S&P 500, Dow Jones Industrial Average, and Nasdaq Composite were all down more than 1% yesterday on fears that inflation was making a comeback, prompting the Federal Reserve to leave its key interest rate unchanged. 

Fundamentals

See More
  • Market Capitalization, $K 155,860,608
  • Shares Outstanding, K 5,686,268
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,118 M
  • EBITDA $ 25,710 M
  • 60-Month Beta 0.47
  • Price/Sales 2.48
  • Price/Cash Flow 6.21
  • Price/Book 1.79

Options Overview Details

View History
  • Implied Volatility 27.27% (+0.13%)
  • Historical Volatility 21.04%
  • IV Percentile 73%
  • IV Rank 26.59%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 7) 0.73 (2.70%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 45,131
  • Volume Avg (30-Day) 104,519
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 2,879,679
  • Open Int (30-Day) 2,674,627
  • Expected Range 26.37 to 27.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.77
  • Number of Estimates 7
  • High Estimate 0.92
  • Low Estimate 0.64
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -16.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.20 +3.65%
on 03/05/26
27.76 -2.18%
on 03/17/26
+0.51 (+1.90%)
since 02/20/26
3-Month
24.83 +9.37%
on 01/02/26
27.94 -2.81%
on 02/13/26
+1.97 (+7.80%)
since 12/19/25
52-Week
20.92 +29.84%
on 04/09/25
27.94 -2.81%
on 02/13/26
+0.97 (+3.69%)
since 03/20/25

Most Recent Stories

More News
Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore

On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their...

ADI : 309.27 (-0.38%)
MCHP : 63.60 (+0.49%)
IVZ : 23.06 (-1.07%)
PFE : 27.05 (-1.31%)
Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.

XLV : 146.28 (-0.23%)
VHT : 271.79 (-0.04%)
$SRHC : 1,701.11 (-0.17%)
PFE : 27.05 (-1.31%)
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease progression or death in HRR gene-mutated metastatic hormone...

PFE : 27.05 (-1.31%)
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile ...

PFE : 27.05 (-1.31%)
Starboard Value Is Betting Big on This Blue-Chip Dividend Stock. Should You?

Starboard does not have a stellar recent record, and Lamb Weston is facing its own issues. Here's what investors need to know about Lamb Weston.

ADSK : 246.87 (-0.31%)
$SPX : 6,556.33 (-0.76%)
LW : 39.92 (-1.77%)
NWS : 27.32 (+0.29%)
PFE : 27.05 (-1.31%)
The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start. Pfizer (PFE) has been a strong performer in 2026 and is up 9.64% so far this year....

PFE : 27.05 (-1.31%)
1 S&P 500 Stock with Promising Prospects and 2 We Avoid

1 S&P 500 Stock with Promising Prospects and 2 We Avoid

NCLH : 19.16 (-2.44%)
STZ : 150.74 (-0.77%)
PFE : 27.05 (-1.31%)
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo ...

PFE : 27.05 (-1.31%)
ParaZero Technologies (NASDAQ: PRZO) Appoints Bat-Sheva Noy as Vice President of Global Sales

ParaZero Technologies (NASDAQ: PRZO) an aerospace defense company focused on smart autonomous solutions for the global manned and unmanned aerial systems industry, announced the appointment of Bat-Sheva...

PRZO : 1.1300 (-0.88%)
PRZ.AX : 0.036 (unch)
PFE : 27.05 (-1.31%)
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease at...

PFE : 27.05 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 28.16
2nd Resistance Point 27.94
1st Resistance Point 27.68
Last Price 27.05
1st Support Level 27.20
2nd Support Level 26.98
3rd Support Level 26.72

See More

52-Week High 27.94
Last Price 27.05
Fibonacci 61.8% 25.26
Fibonacci 50% 24.43
Fibonacci 38.2% 23.60
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar